Medical Condition News

RSS

Breast imaging reports generated with automatic speech recognition more likely to contain errors

Breast imaging reports generated using an automatic speech recognition system are nearly six times more likely to contain major errors than those generated with conventional dictation transcription, a new study in Canada shows.

23 Sep 2011

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.

23 Sep 2011

Researchers discover cellular origins of breast cancer

Identifying the cellular origins of breast cancer might lead to earlier diagnosis and more efficient management of the disease. New research led by Charlotte Kuperwasser of Tufts University School of Medicine (TUSM) has determined that common forms of breast cancer originate from breast cells known as luminal epithelial cells while rarer forms of breast cancer, such as metaplastic carcinomas, originate from basal epithelial cell types.

23 Sep 2011

Cyclin E plays a crucial role in the formation of nerve connections

Scientists at Dana-Farber Cancer Institute and Harvard Medical School have found that a common cancer protein leads a second, totally different life in normal adult brain cells: It helps regulates memory formation and may be implicated in Alzheimer's disease.

23 Sep 2011

Adeno-associated virus type 2 kills human breast cancer cells in lab

A nondisease-causing virus kills human breast cancer cells in the laboratory, creating opportunities for potential new cancer therapies, according to Penn State College of Medicine researchers who tested the virus on three different breast cancer types that represent the multiple stages of breast cancer development.

23 Sep 2011

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-200 was recently granted patents in Singapore and South Africa. These patents significantly strengthen the Adamis APC-200 patent portfolio for the use of APC-200 in the treatment of early and late stage prostate cancer.

23 Sep 2011

Shire announces update on approval status and availability of ProAmatine SOH drug

Shire plc, the global specialty biopharmaceutical company, announces an update on the approval status and availability of ProAmatine (midodrine HCl), a medicine approved for the treatment of symptomatic orthostatic hypotension.

23 Sep 2011

Levosimendan may effectively improve muscle function in patients with respiratory failure

Treatment with the calcium-sensitizing drug levosimendan may be effective in improving muscle function in patients with respiratory muscle weakness, which often accompanies chronic diseases such as chronic obstructive pulmonary disease (COPD) and congestive heart failure, according to researchers in the Netherlands, who studied the effects of the drug on healthy volunteers.

23 Sep 2011

Low levels of vitamin D associated with poorer lung function in children with STRA

Children with severe therapy-resistant asthma (STRA) may have poorer lung function and worse symptoms compared to children with moderate asthma, due to lower levels of vitamin D in their blood, according to researchers in London.

23 Sep 2011

Cedars-Sinai inaugurates new facility to generate induced pluripotent stem cells

The Cedars-Sinai Regenerative Medicine Institute has opened a new Induced Pluripotent Stem Cell (iPSC) Core Facility to produce powerful cells capable of making all tissues of the body from adult human skin cells.

23 Sep 2011

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.

23 Sep 2011

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

23 Sep 2011

Verax Biomedical receives FDA clearance for Platelet PGD test

A $30 test that takes fewer than 30 minutes to perform can prevent potentially deadly transfusions of bacterial contamination in platelets, according to a new study published in the peer-reviewed journal Transfusion. An early view of the study can be found at the journal's web site.

23 Sep 2011

USPTO issues patent for Lixte's LB-100 to treat cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity.

23 Sep 2011

Traffic fumes can raise risk for heart attack for at least six hours: Study

According to British researchers breathing in heavy traffic fumes can trigger a heart attack. Heart attack risk is raised for about six hours post-exposure and goes down again after that, researchers found. They say in the British Medical Journal that pollution probably hastens rather than directly cause attacks. But repeated exposure is still bad for health, they say, substantially shortening life expectancy, and so the advice to people remains the same - avoid as far as is possible.

22 Sep 2011

Depression and stroke: Analysis of studies finds a connect

A latest study shows that people who are depressed may be a little more likely than others to suffer a stroke down the road. Looking at 28 past studies, researchers estimated there would be 106 extra cases of stroke per 100,000 depressed people each year, 22 of them fatal.

22 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1.5 million from the Foundation Fighting Blindness to fund a pre-clinical trial evaluating the safety and efficacy of a gene therapy treatment for X-linked Retinoschisis (XLRS), a genetic eye disease affecting over 35,000 patients in the US and Europe.

22 Sep 2011

U.N. meeting on NCDs concludes with pledges to fight chronic diseases

World leaders on Tuesday "pledged to take wide-ranging action to prevent millions of deaths from cancer, diabetes, and heart and lung disease by tackling the key causes -- smoking, excessive drinking, lack of exercise and unhealthy diets dominated by fast food," but the "declaration approved at the first-ever General Assembly meeting on chronic diseases which ended Tuesday left unanswered the question of coordinating an international response to what the leaders called 'a challenge of epidemic proportions,'" the Associated Press/CBS News reports.

22 Sep 2011

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt's Macular Dystrophy using retinal pigment epithelium (RPE) derived from human embryonic stem cells.

22 Sep 2011

Medical Condition News

Breast imaging reports generated with automatic speech recognition more likely to contain errors

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Researchers discover cellular origins of breast cancer

Cyclin E plays a crucial role in the formation of nerve connections

Adeno-associated virus type 2 kills human breast cancer cells in lab

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Shire announces update on approval status and availability of ProAmatine SOH drug

Levosimendan may effectively improve muscle function in patients with respiratory failure

Low levels of vitamin D associated with poorer lung function in children with STRA

Cedars-Sinai inaugurates new facility to generate induced pluripotent stem cells

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

Verax Biomedical receives FDA clearance for Platelet PGD test

USPTO issues patent for Lixte's LB-100 to treat cancer

Traffic fumes can raise risk for heart attack for at least six hours: Study

Depression and stroke: Analysis of studies finds a connect

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

U.N. meeting on NCDs concludes with pledges to fight chronic diseases

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News